trending Market Intelligence /marketintelligence/en/news-insights/trending/NARf2pTbSCMFNiz477gCpQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Vertex gets EU approval to extend use of cystic fibrosis drug in babies

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Vertex gets EU approval to extend use of cystic fibrosis drug in babies

The European Commission granted extended approval for the use of Vertex Pharmaceuticals Inc.'s Kalydeco in treating infants with cystic fibrosis ages 6 months to up to a year, weighing 5 kilogram and more.

The Boston-based biotechnology company's Kalydeco, also known as ivacaftor, was previously indicated for patients aged one year and older and whose cystic fibrosis is positive for at least one of nine cystic fibrosis transmembrane conductance regulator, or CFTR, gene mutations.

The approval is based on an ongoing phase 3 trial, dubbed Arrival, that is evaluating Kalydeco in infants with cystic fibrosis who are younger than the age of two and have one CFTR gene mutation.

Kalydeco's safety profile is consistent with previous late-stage studies, the company added.

The cystic fibrosis treatment is already approved by the U.S. Food and Drug Administration to treat six-month-old infants and toddlers between the ages of one and two.